These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31385990)

  • 1. Acute neurotoxicity following vincristine due to Charcot-Marie-Tooth disease in a young child with medulloblastoma.
    Kissoon T; Gururangan S; Sladky J
    Neurooncol Pract; 2019 May; 6(3):179-184. PubMed ID: 31385990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe vincristine-induced polyneuropathy in a teenager with anaplastic medulloblastoma and undiagnosed Charcot-Marie-Tooth disease.
    Aghajan Y; Yoon JM; Crawford JR
    BMJ Case Rep; 2017 Apr; 2017():. PubMed ID: 28438772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vincristine exacerbates asymptomatic Charcot-Marie-tooth disease with a novel EGR2 mutation.
    Nakamura T; Hashiguchi A; Suzuki S; Uozumi K; Tokunaga S; Takashima H
    Neurogenetics; 2012 Feb; 13(1):77-82. PubMed ID: 22271166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-induced remission of medulloblastoma using a chemotherapeutic regimen devoid of vincristine in a child with Charcot-Marie-Tooth disease.
    Bernstock JD; Cohen JL; Singh S; Schlappi CW; Fiveash JB; Johnston JM; Fequiere P; Orr BA; Li R; Friedman GK
    Curr Oncol; 2019 Apr; 26(2):e266-e269. PubMed ID: 31043836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A.
    Graf WD; Chance PF; Lensch MW; Eng LJ; Lipe HP; Bird TD
    Cancer; 1996 Apr; 77(7):1356-62. PubMed ID: 8608515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unmasking a Case of Asymptomatic Charcot-Marie-Tooth Disease (CMT1A) With Vincristine.
    Jariwal R; Shoua B; Sabetian K; Natarajan P; Cobos E
    J Investig Med High Impact Case Rep; 2018; 6():2324709618758349. PubMed ID: 29511693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability.
    Ibañez-Juliá MJ; Berzero G; Reyes-Botero G; Maisonobe T; Lenglet T; Slim M; Louis S; Balaguer A; Sanson M; Le Guern E; Latour P; Ricard D; Stojkovic T; Psimaras D
    Acta Oncol; 2018 Mar; 57(3):403-411. PubMed ID: 29243538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterozygosity for CMT Type 4 Predicts a Severe Vincristine-induced Polyneuropathy Phenotype: A Case Report and Review of Literature.
    Sy A; Cheng J; Cooper R; Mueller L
    J Pediatr Hematol Oncol; 2019 Jan; 41(1):e41-e43. PubMed ID: 29877907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapy.
    Hildebrandt G; Holler E; Woenkhaus M; Quarch G; Reichle A; Schalke B; Andreesen R
    Ann Oncol; 2000 Jun; 11(6):743-7. PubMed ID: 10942065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Charcot-Marie-Tooth disease type I diagnosed in a 5-year-old boy after vincristine neurotoxicity, resulting in maternal diagnosis.
    Olek MJ; Bordeaux B; Leshner RT
    J Am Osteopath Assoc; 1999 Mar; 99(3):165-7. PubMed ID: 10217912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vincristine neuropathy: neurophysiological and genetic studies in a case of Wilms tumor.
    Schiavetti A; Frascarelli M; Uccini S; Novelli A
    Pediatr Blood Cancer; 2004 Oct; 43(5):606-9. PubMed ID: 15382281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Acute vincristine neurotoxicity in a non-Hodgkin's lymphoma patient with Charcot-Marie-Tooth disease].
    Uno S; Katayama K; Dobashi N; Hirano A; Ogihara A; Yamazaki H; Usui N; Kobayashi T; Inoue K; Kuraishi Y
    Rinsho Ketsueki; 1999 May; 40(5):414-9. PubMed ID: 10390891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful alternative treatment containing vindesine for acute lymphoblastic leukemia with Charcot-Marie-Tooth disease.
    Ichikawa M; Suzuki D; Inamoto J; Ohshima J; Cho Y; Saitoh S; Kaneda M; Iguchi A; Ariga T
    J Pediatr Hematol Oncol; 2012 Apr; 34(3):239-41. PubMed ID: 22246157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis of hereditary neuropathies.
    Chance PF
    Phys Med Rehabil Clin N Am; 2001 May; 12(2):277-91. PubMed ID: 11345007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular genetics of Charcot-Marie-Tooth disease and related neuropathies.
    Chance PF; Fischbeck KH
    Hum Mol Genet; 1994; 3 Spec No():1503-7. PubMed ID: 7849745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute vincristine neurotoxicity in the presence of hereditary motor and sensory neuropathy type I.
    McGuire SA; Gospe SM; Dahl G
    Med Pediatr Oncol; 1989; 17(6):520-3. PubMed ID: 2685529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic epidemiology of Charcot-Marie-Tooth disease.
    Braathen GJ
    Acta Neurol Scand Suppl; 2012; (193):iv-22. PubMed ID: 23106488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study.
    Chauvenet AR; Shashi V; Selsky C; Morgan E; Kurtzberg J; Bell B;
    J Pediatr Hematol Oncol; 2003 Apr; 25(4):316-20. PubMed ID: 12679647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic evaluation of inherited motor/sensory neuropathy.
    Chance PF
    Suppl Clin Neurophysiol; 2004; 57():228-42. PubMed ID: 16106622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inherited peripheral neuropathy.
    Keller MP; Chance PF
    Semin Neurol; 1999; 19(4):353-62. PubMed ID: 10716658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.